Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Accumulated Expenses (2017 - 2025)

Catalyst Pharmaceuticals' Other Accumulated Expenses history spans 9 years, with the latest figure at $840000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 101.44% year-over-year to $840000.0; the TTM value through Dec 2025 reached $840000.0, up 101.44%, while the annual FY2025 figure was $840000.0, 101.44% up from the prior year.
  • Other Accumulated Expenses reached $840000.0 in Q4 2025 per CPRX's latest filing, roughly flat from $842000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $2.2 million in Q1 2025 to a low of $372000.0 in Q2 2024.
  • Average Other Accumulated Expenses over 3 years is $794625.0, with a median of $606000.0 recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: dropped 10.32% in 2024, then skyrocketed 101.44% in 2025.
  • A 3-year view of Other Accumulated Expenses shows it stood at $465000.0 in 2023, then fell by 10.32% to $417000.0 in 2024, then surged by 101.44% to $840000.0 in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Other Accumulated Expenses are $840000.0 (Q4 2025), $842000.0 (Q3 2025), and $747000.0 (Q2 2025).